|
[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
|
|
[2]Mc GLYNN KA, PETRICK JL, LONDON WT.Global epidemiology of hepatocellular carcinoma:An emphasis on demographic and regional variability[J].Clin Liver Dis, 2015, 19 (2) :223-238.
|
|
[3]WOJCIECHOWSKA J, KRAJEWSKI W, BOLANOWSKI M, et al.Diabetes and cancer:A review of current knowledge[J].Exp Clin Endocrinol Diabetes, 2016, 124 (5) :263-275.
|
|
[4]NAGAOKI Y, HYOGO H, AIKATA H, et al.Recent trend of clinical features in patients with hepatocellular carcinoma[J].Hepatol Res, 2012, 42 (4) :368-375.
|
|
[5]CHEN J, HAN Y, XU C, et al.Effect of type 2 diabetes mellitus on the Risk for hepatocellular carcinoma in chronic liver diseases:A meta-analysis of cohort studies[J].Eur J Cancer Prev, 2015, 24 (2) :89-99.
|
|
[6]LI X, WANG X, GAO P.Diabetes mellitus and risk of hepatocellular carcinoma[J].Biomed Res Int, 2017, 2017:5202684.
|
|
[7]LIANG J, HAN T.Diabetes mellitus and primary liver cancer:Risk factor or real cause?[J].J Clin Hepatol, 2017, 33 (4) :757-762. (in Chinese) 梁静, 韩涛.糖尿病与原发性肝癌:危险因素还是致病病因?[J].临床肝胆病杂志, 2017, 33 (4) :757-762.
|
|
[8]LIU C, ZHANG Z, TANG H, et al.Crosstalk between IGF-1R and other tumor promoting pathways[J].Curr Pharm Des, 2014, 20 (17) :2912-2921.
|
|
[9]JABIR NR, AHMAD S, TABREZ S.An insight on the association of glycation with hepatocellular carcinoma[J].Semin Cancer Biol, 2018, 49:56-63.
|
|
[10]AGOSTI P, SABBAC, MAZZOCCA A.Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment[J].Biochim Biophys Acta, 2018, 1864 (2) :607-617.
|
|
[11]MO XL, LIU J, ZHU JY, et al.Value of transforming growth factor-β1 in diagnosis of primary liver cancer:A meta-analysis[J].J Clin Hepatol, 2017, 33 (5) :864-868. (in Chinese) 莫晓丽, 刘洁, 诸佳瑜, 等.TGFβ1对原发性肝癌诊断价值的Meta分析[J].临床肝胆病杂志, 2017, 33 (5) :864-868.
|
|
[12]LI XF, CHEN C, XIANG DM, et al.Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance[J].Hepatology, 2017, 66 (6) :1934-1951.
|
|
[13]MITRA A, YAN J, XIA X, et al.IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficientβ2-spectrin+/-mice[J].Hepatology, 2017, 65 (4) :1222-1236.
|
|
[14]QIAO B, ZHOU Y, SHI CH, et al.Mechanisms and treatment progress of hepatogenous diabetes[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :21-25. (in Chinese) 乔兵, 周永, 史昌河, 等.肝源性糖尿病诊疗进展[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :21-25.
|
|
[15]RUSTEMOGLU A, ERKOL INAL E, INANIR A, et al.Clinical significance of NCOA5 gene rs2903908 polymorphism in Behcet's disease[J].EXCLI J, 2017, 16:609-617.
|
|
[16]PELEKANOU V, KAMPA M, KIAGIADAKI F, et al.Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1[J].J Leukoc Biol, 2016, 99 (2) :333-347.
|
|
[17]NAUGLER WE, SAKURAI T, KIM S, et al.Gender disparity in liver cancer due to sex differences in My D88-dependent IL-6 production[J].Science, 2007, 317 (5834) :121-124.
|
|
[18]FACCIORUSSO A, BARONE M.Glucose intolerance and hepatocellular carcinoma:Recent findings for old diseases[J].Hepatobiliary Surg Nutr, 2014, 3 (2) :91-92.
|
|
[19]GAO S, LI A, LIU F, et al.NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma[J].Cancer Cell, 2013, 24 (6) :725-737.
|
|
[20]LIU X, LIU F, GAO S, et al.A single non-synonymous NCOA5variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation[J].Cancer Lett, 2017, 391:152-161.
|
|
[21]LEWIS JP, PALMER ND, ELLINGTON JB, et al.Analysis of candidate genes on chromosome 20q12-13.1 reveals evidence for BMI mediated association of PREX1 with type 2 diabetes in European Americans[J].Genomics, 2010, 96 (4) :211-219.
|
|
[22]JIN T.Current understanding on role of the wnt signaling pathway effector TCF7L2 in glucose homeostasis[J].Endocr Rev, 2016, 37 (3) :254-277.
|
|
[23]OSMARK P, HANSSON O, JONSSON A, et al.Unique splicing pattern of the TCF7L2 gene in human pancreatic islets[J].Diabetologia, 2009, 52 (5) :850-854.
|
|
[24]LE BACQUER O, SHU L, MARCHAND M, et al.TCF7L2 splice variants have distinct effects on beta-cell turnover and function[J].Hum Mol Genet, 2011, 20 (10) :1906-1915.
|
|
[25]RIZVI S, RAZA ST, RAHMAN Q, et al.Role of GNB3, NET, KCNJ11, TCF7L2 and GRL genes single nucleotide polymorphism in the risk prediction of type 2 diabetes mellitus[J].3 Biotech, 2016, 6 (2) :255.
|
|
[26]IBRAHIM AT, HUSSAIN A, SALIH MA, et al.Candidate gene analysis supports a role for polymorphisms at TCF7L2 as risk factors for type2 diabetes in Sudan[J].J Diabetes Metab Disord, 2016, 15:4.
|
|
[27]ISHIGURO H, WAKASUGI T, TERASHITA Y, et al.Nuclear expression of TCF4/TCF7L2 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma[J].Cell Mol Biol Lett, 2016, 21:5.
|
|
[28]LING Q, DONG F, GENG L, et al.Impacts of TCF7L2 gene polymorphisms on the susceptibility of hepatogenous diabetes and hepatocellular carcinoma in cirrhotic patients[J].Gene, 2013, 522 (2) :214-218.
|
|
[29]YOUNESS RA, EL-TAYEBI HM, ASSAL RA, et al.MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream m TOR, STAT3and c-Myc[J].Oncol Lett, 2016, 12 (4) :2567-2573.
|
|
[30]ZENG X, HUANG H, TAMAI K, et al.Initiation of Wnt signaling:Control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions[J].Development, 2008, 135 (2) :367-375.
|
|
[31]AMPUERO J, ROMERO-GOMEZ M.Prevention of hepatocellular carcinoma by correction of metabolic abnormalities:Role of statins and metformin[J].World J Hepatol, 2015, 7 (8) :1105-1111.
|
|
[32]QIU J, FU YF.Glycogen synthase kinase-3 and tumorigenesis[J].J Int Oncol, 2010, 37 (6) :416-419. (in Chinese) 邱建, 傅云峰.糖原合成激酶-3β与肿瘤的发生发展[J].国际肿瘤学杂志, 2010, 37 (6) :416-419.
|
|
[33]VILCHEZ V, TURCIOS L, MARTI F, et al.Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment[J].World J Gastroenterol, 2016, 22 (2) :823-832.
|
|
[34]QIAO G, LE Y, LI J, et al.Glycogen synthase kinase-3βis associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma[J].PLo S One, 2014, 9 (8) :e105624.
|
|
[35]WU YJ, GUO JS.Hepatic stellate cells, Toll-like receptor 4 signaling pathway, and inflammatory fibrotic microenvironment in the development of hepatocellular carcinoma[J].J Clin Hepatol, 2015, 31 (6) :876-879. (in Chinese) 吴玉婧, 郭津生.肝星状细胞、Toll样受体4信号途径、炎症及纤维化微环境与原发性肝癌发生发展的关系[J].临床肝胆病杂志, 2015, 31 (6) :876-879.
|
|
[36]HWANG DH, KIM JA, LEE JY.Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid[J].Eur J Pharmacol, 2016, 785:24-35.
|
|
[37]CHEN H, LIU Y, LI D, et al.PGC-1βsuppresses saturated fatty acid-induced macrophage inflammation by inhibiting TAK1 activation[J].IUBMB Life, 2016, 68 (2) :145-155.
|
|
[38]MAMEDOVA LK, YUAN K, LAUDICK AN, et al.Toll-like receptor 4 signaling is required for induction of gluconeogenic gene expression by palmitate in human hepatic carcinoma cells[J].J Nutr Biochem, 2013, 24 (8) :1499-1507.
|
|
[39]DASU MR, DEVARAJ S, PARK S, et al.Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type2 diabetic subjects[J].Diabetes Care, 2010, 33 (4) :861-868.
|
DownLoad: